Exosomes as Reconfigurable Therapeutic Systems

Trends in Molecular Medicine

Volumn 23, Issue 7, 2017, Pages 636-650

  Conlan, R Steven ^a   Pisano, Simone ^a,b   Oliveira, Marta I ^c   Ferrari, Mauro ^d   Mendes Pinto, Inês ^c  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF TRIESTE   (Italy)

^c INTERNATIONAL IBERIAN NANOTECHNOLOGY LABORATORY   (Portugal)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; DOXORUBICIN; NANOPARTICLE; POLYMER; RECOMBINANT INTERLEUKIN 10; DRUG CARRIER;

ARTHRITIS; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL COMMUNICATION; CELL COMPOSITION; CELL CONTACT; CELL FUNCTION; CELL ISOLATION; CELL STRUCTURE; CIRCULATION; CLINICAL EFFECTIVENESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EXOSOME; HUMAN; IN VIVO STUDY; LIVER METASTASIS; LUNG METASTASIS; MELANOMA; NONHUMAN; ORGANELLE BIOGENESIS; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; METABOLISM;

ANIMALS; DRUG CARRIERS; EXOSOMES; HUMANS; NANOPARTICLES;

EID: 85021094586     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2017.05.003     Document Type: Review

References (100)

1. Ren, J., et al. From structures to functions: insights into exosomes as promising drug delivery vehicles. Biomater. Sci. 4 (2016), 910–921.
2. Kourembanas, S., Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annu. Rev. Physiol. 77 (2015), 13–27.
3. Record, M., et al. Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies. Biochim. Biophys. Acta 1841 (2014), 108–120.
4. Dutta, S., et al. Proteomics profiling of cholangiocarcinoma exosomes: a potential role of oncogenic protein transferring in cancer progression. Biochim. Biophys. Acta 1852 (2015), 1989–1999.
5. Ung, T.H., et al. Exosome proteomics reveals transcriptional regulator proteins with potential to mediate downstream pathways. Cancer Sci. 105 (2014), 1384–1392.
6. Palma, J., et al. MicroRNAs are exported from malignant cells in customized particles. Nucleic Acids Res. 40 (2012), 9125–9138.
7. Willms, E., et al. Cells release subpopulations of exosomes with distinct molecular and biological properties. Sci. Rep., 6, 2016, 22519.
8. Segura, E., et al. Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells Mol. Dis. 35 (2005), 89–93.
9. Kilpinen, L., et al. Extracellular membrane vesicles from umbilical cord blood-derived MSC protect against ischemic acute kidney injury, a feature that is lost after inflammatory conditioning. J. Extracell. Vesicles 2 (2013), 1–15.
10. de Jong, O.G., et al. Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes. J. Extracell. Vesicles 1 (2012), 1–12.
11. Kucharzewska, P., et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 7312–7317.
12. Yang, T., et al. Exosome delivered anticancer drugs across the blood–brain barrier for brain cancer therapy in Danio rerio. Pharm. Res. 32 (2015), 2003–2014.
13. Li, S.-D., Huang, L., Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim. Biophys. Acta 1788 (2009), 2259–2266.
14. Maeda, H., Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 91 (2015), 3–6.
15. Ayala, V., et al. Effect of surface charge on the colloidal stability and in vitro uptake of carboxymethyl dextran-coated iron oxide nanoparticles. J. Nanopart. Res., 15, 2013, 1874.
16. Xiao, K., et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 32 (2011), 3435–3446.
17. Miao, Y., et al. A TRP channel senses lysosome neutralization by pathogens to trigger their expulsion. Cell 161 (2015), 1306–1319.
18. Atayde, V.D., et al. Exosome secretion by the parasitic protozoan Leishmania within the sand fly midgut. Cell Rep. 13 (2015), 957–967.
19. Srikanthan, S., et al. Exosome poly-ubiquitin inhibits platelet activation, downregulates CD36 and inhibits pro-atherothombotic cellular functions. J. Thromb. Haemost. 12 (2014), 1906–1917.
20. Lee, C., et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 126 (2012), 2601–2611.
21. Salomon, C., et al. Exosomal signaling during hypoxia mediates microvascular endothelial cell migration and vasculogenesis. PLoS One, 8, 2013, e68451.
22. Kang, K., et al. Exosomes secreted from CXCR4 overexpressing mesenchymal stem cells promote cardioprotection via Akt signaling pathway following myocardial infarction. Stem Cells Int., 2015, 2015, 659890.
23. Hu, L., et al. Exosomes derived from human adipose mensenchymal stem cells accelerates cutaneous wound healing via optimizing the characteristics of fibroblasts. Sci. Rep., 6, 2016, 32993.
24. Nakamura, Y., et al. Mesenchymal-stem-cell-derived exosomes accelerate skeletal muscle regeneration. FEBS Lett. 589 (2015), 1257–1265.
25. Baglio, S.R., et al. Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. Stem Cell Res. Ther., 6, 2015, 127.
26. Smith, V.L., et al. Exosomes function in antigen presentation during an in vivo Mycobacterium tuberculosis infection. Sci. Rep., 7, 2017, 43578.
27. Beltrami, C., et al. Human pericardial fluid contains exosomes enriched with cardiovascular-expressed microRNAs and promotes therapeutic angiogenesis. Mol. Ther. 25 (2017), 679–693.
28. Lai, R.C., et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 4 (2010), 214–222.
29. Sarkar, A., et al. Monocyte derived microvesicles deliver a cell death message via encapsulated caspase-1. PLoS One, 4, 2009, e7140.
30. Ristorcelli, E., et al. Human tumor nanoparticles induce apoptosis of pancreatic cancer cells. FASEB J. 22 (2008), 3358–3369.
31. + T-cell apoptosis. Blood Cells Mol. Dis. 35 (2005), 169–173.
32. Rak, J., Guha, A., Extracellular vesicles – vehicles that spread cancer genes. Bioessays 34 (2012), 489–497.
33. Costa-Silva, B., et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 17 (2015), 816–826.
34. Tian, T., et al. Dynamics of exosome internalization and trafficking. J. Cell Physiol. 228 (2013), 1487–1495.
35. Tian, Y., et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35 (2014), 2383–2390.
36. Zhuang, X., et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol. Ther. 19 (2011), 1769–1779.
37. Munagala, R., et al. Bovine milk-derived exosomes for drug delivery. Cancer Lett. 371 (2016), 48–61.
38. Goetzl, E.J., et al. Human plasma platelet-derived exosomes: effects of aspirin. FASEB J. 30 (2016), 2058–2063.
39. Kim, S.-H., et al. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J. Immunol. 174 (2005), 6440–6448.
40. Kapustin, A.N., et al. Vascular smooth muscle cell calcification is mediated by regulated exosome secretion. Circ. Res. 116 (2015), 1312–1323.
41. Zitvogel, L., et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 4 (1998), 594–600.
42. Shimbo, K., et al. Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration. Biochem. Biophys. Res. Commun. 445 (2014), 381–387.
43. Peng, D., et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527 (2015), 249–253.
44. Liu, R., et al. Synthetic nucleic acids delivered by exosomes: a potential therapeutic for gene related metabolic brain diseases. Metab. Brain Dis. 28 (2013), 551–562.
45. EL Andaloussi, S., et al. Exosomes for targeted siRNA delivery across biological barriers. Adv. Drug Deliv. Rev 65 (2013), 391–397.
46. Alvarez-Erviti, L., et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29 (2011), 341–345.
47. Qazi, K.R., et al. Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism. Blood 113 (2009), 2673–2683.
48. Gehrmann, U., et al. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes. Cancer Res. 73 (2013), 3865–3876.
49. Hudry, E., et al. Exosome-associated AAV vector as a robust and convenient neuroscience tool. Gene Ther. 4 (2016), 380–392.
50. Kim, M.S., et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12 (2015), 655–664.
51. Yu, D.D., et al. Exosomes in development, metastasis and drug resistance of breast cancer. Cancer Sci. 106 (2015), 959–964.
52. Robbins, P.D., Morelli, A.E., Regulation of Immune Responses by Extracellular Vesicules. Nat. Immunol. 14 (2014), 195–208.
53. Roma-Rodrigues, C., et al. Exosome in tumour microenvironment: overview of the crosstalk between normal and cancer cells. Biomed. Res. Int., 2014, 2014, 179486.
54. Peinado, H., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18 (2012), 883–891.
55. Yu, D.D., et al. Exosomes from adriamycin-resistant breast cancer cells transmit drug resistance partly by delivering miR-222. Tumor Biol. 37 (2015), 3227–3235.
56. Deng, Z., et al. Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance. Diabetes 58 (2009), 2498–2505.
57. Mora, E.M., et al. Biobanking of exosomes in the era of precision medicine: are we there yet?. Int. J. Mol. Sci. 17 (2015), 1–13.
58. Hanna, E., et al. Advanced therapy medicinal products: current and future perspectives. J. Mark. Access Health Policy, 4, 2016, 31036.
59. Takahashi, Y., et al. Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. J. Biotechnol. 165 (2013), 77–84.
60. Bala, S., et al. Biodistribution and function of extracellular miRNA-155 in mice. Sci. Rep., 5, 2015, 10721.
61. Hiltbrunner, S., et al. Exosomal cancer immunotherapy is independent of MHC molecules on exosomes. Oncotarget 7 (2016), 38707–38717.
62. McKelvey, K.J., et al. Exosomes: mechanisms of uptake. J. Circ. Biomarkers, 4, 2015, 1.
63. Hoshino, A., et al. Tumour exosome integrins determine organotropic metastasis. Nature 527 (2015), 329–335.
64. Jeong, D., et al. Nanovesicles engineered from ES cells for enhanced cell proliferation. Biomaterials 35 (2014), 9302–9310.
65. Jo, W., et al. Microfluidic fabrication of cell-derived nanovesicles as endogenous RNA carriers. Lab Chip 14 (2014), 1261–1269.
66. Jang, S.C., et al. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano 7 (2013), 7698–7710.
67. Sato, Y.T., et al. Engineering hybrid exosomes by membrane fusion with liposomes. Sci. Rep., 6, 2016, 21933.
68. Xu, R., et al. An injectable nanoparticle generator enhances delivery of cancer therapeutics. Nat. Biotechol. 34 (2016), 414–418.
69. Wolfram, J., et al. Multistage vector (MSV) therapeutics. J. Control. Release 219 (2015), 406–415.
70. Xu, R., et al. An injectable nanoparticle generator enhances delivery of cancer therapeutics. Nat. Biotechol. 34 (2016), 414–418.
71. Harding, C., et al. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 97 (1983), 329–339.
72. Pan, B.T., et al. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J. Cell Biol. 101 (1985), 942–948.
73. Trams, E.G., et al. Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. Biochim. Biophys. Acta 645 (1981), 63–70.
74. Colombo, M., et al. Biogenesis, secretion, and intercellular Interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30 (2014), 255–289.
75. Babst, M., et al. Endosome-associated complex, ESCRT-II, recruits transport machinery for protein sorting at the multivesicular body. Dev. Cell 3 (2002), 283–289.
76. Buschow, S.I., et al. MHC II In dendritic cells is targeted to lysosomes or t cell-induced exosomes via distinct multivesicular body pathways. Traffic 10 (2009), 1528–1542.
77. Carayon, K., et al. Proteolipidic composition of exosomes changes during reticulocyte maturation. J. Biol. Chem. 286 (2011), 34426–34439.
78. Raposo, G., et al. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 183 (1996), 1161–1172.
79. Chaput, N., Théry, C., Exosomes: immune properties and potential clinical implementations. Semin. Immunopathol. 33 (2011), 419–440.
80. Valadi, H., et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9 (2007), 654–659.
81. Liu, Y., et al. Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse. Sci. Rep., 5, 2015, 17543.
82. Cho, J.A., et al. Exosomes: a new delivery system for tumor antigens in cancer immunotherapy. Int. J. Cancer 114 (2005), 613–622.
83. Rivoltini, L., et al. TNF-related apoptosis-inducing ligand (TRAIL)-armed exosomes deliver pro-apoptotic signals to tumor site. Clin. Cancer Res. 22 (2016), 3499–3512.
84. Delcayre, A., et al. Exosome display technology: applications to the development of new diagnostics and therapeutics. Blood Cells Mol. Dis. 35 (2005), 158–168.
85. Rountree, R.B., et al. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 71 (2011), 5235–5244.
86. Smyth, T., et al. Surface functionalization of exosomes using click chemistry. Bioconjug. Chem. 25 (2014), 1777–1784.
87. Villarroya-beltri, C., et al. Sorting it out: regulation of exosome loading. Semin. Cancer Biol. 28 (2014), 3–13.
88. Hoshino, D., et al. Exosome secretion is enhanced by invadopodia and drives invasive behavior. Cell Rep. 5 (2013), 1159–1168.
89. Caldieri, G., Buccione, R., Aiming for invadopodia: organizing polarized delivery at sites of invasion. Trends Cell Biol. 20 (2010), 64–70.
90. Sinha, S., et al. Cortactin promotes exosome secretion by controlling branched actin dynamics. J. Cell Biol. 214 (2016), 197–213.
91. Gangoda, L., Mathivanan, S., Cortactin enhances exosome secretion without altering cargo. J. Cell Biol. 214 (2016), 129–131.
92. D'Souza-Schorey, C., Clancy, J.W., Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes. Dev. 26 (2012), 1287–1299.
93. Muralidharan-Chari, V., et al. ARF6-regulated shedding of tumor cell derived plasma membrane microvesicles. Curr. Biol. 19 (2009), 1875–1885.
94. Muralidharan-Chari, V., et al. Microvesicles: mediators of extracellular communication during cancer progression. J. Cell Sci. 123 (2010), 1603–1611.
95. Mittelbrunn, M., et al. Organizing polarized delivery of exosomes at synapses. Traffic 16 (2015), 327–337.
96. Aoyagi, K., et al. The activation of exocytotic sites by the formation of phosphatidylinositol 4, 5-bisphosphate microdomains at syntaxin clusters. J. Biol. Chem. 280 (2005), 17346–17352.
97. Martin, T.F., PI(4,5)P-binding effector proteins for vesicle exocytosis. Biochim. Biophys. Acta 1851 (2015), 785–793.
98. Escudier, B., et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J. Transl. Med., 3, 2005, 10.
99. Morse, M.A., et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med., 3, 2005, 9.
100. Dai, S., et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol. Ther. 16 (2008), 782–790.